Room to grow: tumor-germline sequencing
February 2025—Genetic profiling has long had proven winners in oncology: somatic testing of tumors, and germline testing for surveillance and to identify potentially affected relatives.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
February 2025
The shift from cotesting to primary HPV screening
February 2025—Eric Huang, MD, PhD, is the first to admit that when it came time to switch to primary HPV testing, his laboratory at the University of Washington faced fewer obstacles than most. Dr. Huang joined the university in 2018 as director of the cytopathology laboratory.
In chemistry and more, what to know about new checklist edition
February 2025—In the 2024 accreditation program checklist edition, released Dec. 26, are new and revised requirements for chemistry, diagnostic immunology, and flow cytometry laboratories. Two of the flow cytometry requirements are now also in the anatomic pathology checklist.
USCAP meeting presenters take us inside for early look
February 2025—HER2 in predictive biomarker testing, HPV-related cancer testing guidelines, and the art of applying polygenic risk scores will be some of what’s heard in USCAP 2025 sessions next month in Boston.
AMP case report: A 67-year-old female with rare intracranial mesenchymal tumor featuring the EWSR1::CREM fusion gene
February 2025—Intracranial mesenchymal tumors (IMT) are extremely rare and account for only 0.3 percent of soft tissue tumors. Most frequently, mesenchymal tumors occur in subcutaneous tissue; they are rarely described in the central nervous system. In addition, these tumors typically occur in young adults,1 with a median patient age of 14 (range: four to 70).
Requirement changes in microbiology, transfusion checklists
February 2025—Some of the CAP accreditation program requirements in the 2024 microbiology and transfusion medicine checklists, in the edition released Dec. 26, have been revised to simplify, clarify, and conserve resources. In transfusion, one new requirement was added to define policy requirements for the use of low-titer group O whole blood.
Views on digital pathology, AI, and the AP LIS
February 2025—Digital pathology, artificial intelligence, and anatomic pathology computer systems—seven participants in a Dec. 10, 2024 online roundtable talked with CAP TODAY publisher Bob McGonnagle about their experiences, plans, and predictions. Large academic center practices and small pathology practices—they considered all perspectives. Here is what they told us.
From the President’s Desk
February 2025—Five years ago, many of us were grappling with the earliest cases of a novel coronavirus in the United States. During the COVID-19 pandemic that ensued, we pathologists became more visible in a variety of ways, both to our clinical colleagues and to the general public.
Anatomic pathology selected abstracts
February 2025—Pulmonary complications cause significant morbidity and mortality in post-hematopoietic stem cell transplantation. The histopathology of pulmonary diseases in the context of post-hematopoietic stem cell transplantation (post-HSCT) is poorly characterized, especially in the pediatric population. The authors sought to characterize the pathologic spectrum of pulmonary disease post-HSCT in a pediatric cohort. Fifty-six specimens, including 53 biopsy specimens, corresponding to 53 patients were identified. Biopsy slides were reviewed and assigned to diagnostic categories (infectious, graft-versus-host disease, vasculopathy, indeterminate, and others) by consensus among three pediatric pulmonary pathologists, taking into consideration pathologic, clinical, radiologic, and laboratory findings.
Clinical pathology selected abstracts
February 2025—Low titer group O whole blood is commonly used for severe bleeding in trauma patients. It may also benefit pediatric patients undergoing cardiopulmonary bypass who are at risk for massive bleeding and coagulopathies. Circuit anticoagulation, hypothermia, hemodilution, coagulation factor, platelet loss and dysfunction, an underdeveloped hemostasis system in patients younger than two years old, and other factors lead to a higher risk of bleeding. Compared with component therapy, whole blood contains higher concentrations of RBCs, platelets, and coagulation factors, as well as cold platelets with enhanced hemostatic function. Due to the logistical challenges of donor centers providing ABO-specific whole blood for cardiopulmonary bypass (CPB), the use of longer storage-age low titer group O whole blood (LTOWB) may be an option for younger pediatric patients with severe bleeding on CPB.